<code id='7BA2D0DB7D'></code><style id='7BA2D0DB7D'></style>
    • <acronym id='7BA2D0DB7D'></acronym>
      <center id='7BA2D0DB7D'><center id='7BA2D0DB7D'><tfoot id='7BA2D0DB7D'></tfoot></center><abbr id='7BA2D0DB7D'><dir id='7BA2D0DB7D'><tfoot id='7BA2D0DB7D'></tfoot><noframes id='7BA2D0DB7D'>

    • <optgroup id='7BA2D0DB7D'><strike id='7BA2D0DB7D'><sup id='7BA2D0DB7D'></sup></strike><code id='7BA2D0DB7D'></code></optgroup>
        1. <b id='7BA2D0DB7D'><label id='7BA2D0DB7D'><select id='7BA2D0DB7D'><dt id='7BA2D0DB7D'><span id='7BA2D0DB7D'></span></dt></select></label></b><u id='7BA2D0DB7D'></u>
          <i id='7BA2D0DB7D'><strike id='7BA2D0DB7D'><tt id='7BA2D0DB7D'><pre id='7BA2D0DB7D'></pre></tt></strike></i>

          Home / entertainment / focus

          focus


          focus

          author:entertainment    Page View:2517
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In